Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children

Pediatric Blood and Cancer

Volumn 43, Issue 5, 2004, Pages 560-567

  Joseph, Thomas ^a   Kusumakumary, P ^a   Chacko, Priya ^a   Abraham, Annie ^b   Pillai, M Radhakrishna ^a  

^a REGIONAL CANCER CENTRE   (India)

^b UNIVERSITY OF KERALA   (India)

Author keywords

Cytochrome P450 (CYP); Glutathione S transferase (GST); Polymorphisms

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 2D6; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BIOTRANSFORMATION; CANCER RISK; CANCER SUSCEPTIBILITY; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DNA SEQUENCE; DRUG METABOLISM; ETHNOLOGY; FEMALE; GENE DELETION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; INDIA; INFANT; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; XENOBIOTIC METABOLISM;

ADOLESCENT; BIOTRANSFORMATION; CARCINOGENS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2D6; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; INDIA; INFANT; INFANT, NEWBORN; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; ODDS RATIO; XENOBIOTICS;

EID: 4744363964     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20074     Document Type: Article

References (62)

1. Regional Cancer Centre, 2002. Thiruvananthapuram-Annual Report 2001-2002. pp 14-15.
2. Miller MC, Mohrenweiser HW, Bell DA. Genetic variability in susceptibility and response to toxicants. Toxicol Lett 2001;120:269-280.
3. Guengerich FP, Shimada T, Raney KD, et al. Elucidation of catalytic specificities of human cytochrome P450 and glutathione S-transferase enzymes and relevance to molecular epidemiology. Environ Health Perspect 1992;98:75-80.
4. Carmella SG, Borukhova A, Akerkar SA, et al. Analysis of human urine for pyridine-N-oxide metabolites of 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific lung carcinogen. Cancer Epidemiol Biomarkers Prev 1997;6:113-120.
5. Autrup H. Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. Mutat Res 2000;464:65-76.
6. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
7. Goeptar AR, Scheerens H, Vermeulen NPE. Oxygen and xenobiotic reductase activities of cytochrome P450. Crit Rev Toxicol 1995;25:25-65.
8. Guengerich FP. Metabolic activation of carcinogens. Pharmacol Ther 1992;54:17-61.
9. Gonzalez FJ, Gelboin HV. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 1994;26:165-183.
10. Persson I, Johansson M, Ingelman-Sundberg M. In vitro kinetics of two human variant CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun 1997;231:227-230.
11. Kagimoto M, Heim M, Kagimoto K, et al. Multiple mutations of the human Cytochrome P450IID6 (CYP2D6) in poor metabolizers of debrisoquine. J Biol Chem 1990;265:17209-17214.
12. Hanioka N, Kimura S, Meyer UA, et al. The human CYP2D locus associated with a common genetic defect in drug oxidation, a G1934 → A base change in introns 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet 1990;47:994-1001.
13. Gough AC, Miles JS, Spurr NK, et al. Identification of the primary gene defect at the Cytochrome P450 CYP2D locus. Nature 1990;347:773-776.
14. Smith CAD, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339:1375-1377.
15. Ketterer B, Harris JM, Talaska G, et al. The glutathione S-transferase supergene family, its polymorphism and its effects on susceptibility to lung cancer. Environ Health Perspect 1992;98:87-94.
16. Rushmore TH, Pickett CB. GSTs, structure, regulation and therapeutic implications. J Biol Chem 1993;268:11475-11478.
17. Seidegard J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 1988;85:7293-7297.
18. Pemble S, Schroeder KR, Spencer SR, et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994;300:271-276.
19. Mannervik B, Danielson UH. Glutathione transferases - Structure and catalytic activity. CRC Crit Rev Biochem 1988;23:283-337.
20. Bailey LR, Roodi N, Verrier CS, et al. Breast cancer and CYP1A1, GSTM1, and GSTT1 polymorphisms: Evidence of a lack of association in Caucasians and African Americans. Cancer Res 1998;58:65-70.
21. Tanimoto K, Hayashi S, Yoshiga K, et al. Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose. Oral Oncol 1999;35:191-196.
22. Krajinovic M, Labuda D, Richer C, et al. Susceptibility to childhood acute lymphoblastic leukemia: Influence of CYP1A1, CYP2D6, GSTM1 and GSTT1 genetic polymorphisms. Blood 1999;93:1496-1501.
23. Chen C, Liu Q, Relling MV. Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American Whites and Blacks. Pharmacogenetics 1996;6:187-191.
24. Whyatt RM, Perera FP. Application of biologic markers to studies of environmental risks in children and the developing fetus. Environ Health Perspect 1995;103:105-110.
25. Neglia JP, Robison LL. Epidemiology of the childhood acute leukemias. Pediatr Clin North Am 1988;35:675-692.
26. Linet MS, Devesa SS. Descriptive epidemiology of childhood leukaemia. Br J Cancer 1991;63:424-429.
27. Juchau MR. Drug biotransformation in the placenta. Pharmacol Ther 1980;8:501-524.
28. Hakkola J, Pelkonen O, Pasanen M, et al. Xenobiotic metabolizing cytochrome P450 enzymes in the human feto-placental unit: Role in intrauterine toxicity. Crit Rev Toxicol 1998;28:35-72.
29. Lowengart RA, Peters JM, Cicioni C, et al. Childhood leukemia and parents' occupational and home exposures. J Natl Cancer Inst 1987;79:39-46.
30. Leiss JK, Savitz DA. Home pesticide use and childhood cancer: A case-control study. Am J Public Health 1995;85:249-252.
31. Daniels JL, Olshan AF, Savitz DA, et al. Pesticides and childhood cancers. Environ Health Perspect 1997;105:1068-1077.
32. Buckley JD, Buckley CM, Ruccione K, et al. Epidemoilogical characteristics of childhood acute lymphocytic leukemia: Analysis by immunophenotype, the childrens' cancer group. Leukemia 1994;8:856-864.
33. Perera FP. Environment and cancer: Who are susceptible? Science 1997;278:1068-1073.
34. Sinnett D, Krajinovic M, Labuda D. Genetic susceptibility to childhood acute lymphoblastic leukemia. Leuk Lymphoma 2000;38:447-462.
35. Cascorbi I, Brockmoller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1. Population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996;56:4965-4969.
36. Cosma G, Crofts F, Taioli E, et al. Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health 1993;40:309-316.
37. Blumer JL, Dunn R, Esterhay MD, et al. Lymphocyte aromatic hydrocarbon responsiveness in acute leukemia of childhood. Blood 1981;58:1081-1088.
38. Kawajiri K, Nakachi K, Imai K, et al. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501 A1 gene. FEBS Lett 1990;263:131-133.
39. Song N, Tan W, Xing D, et al. CYP1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: A case-control study in China. Carcinogenesis 2001;22:11-16.
40. Taioli E, Gaspari L, Benhamou S, et al. Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. Int J Epidemiol 2003;32:60-63.
41. Sreelekha TT, Ramadas K, Pandey M, et al. Genetic polymorphism of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer. Oral Oncol 2001;37:593-598.
42. Vineis P. The relationship between polymorphisms of xenobiotic metabolizing enzymes and susceptibility to cancer. Toxicology 2002;181-182:457-462.
43. Infante-Rivard C, Krajinovic M, Labuda D, et al. Parental smoking, CYP1A1 genetic polymorphisms and childhood leukemia (Quebec, Canada). Cancer Causes Control 2000;11:547-553.
44. Buch S, Kotekar A, Kawle D, et al. Polymorphisms at CYP and GST loci. Prevalence in the Indian population. Eur J Clin Pharmacol 2001;57:553-555.
45. Guengerich FP. Cytochrome P450 enzymes. Am Sci 1993;81:440-447.
46. Sachse C, Brockmöller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and the phenotypic consequences. Am J Hum Genet 1997;60:284-295.
47. Sachse C, Brockmöller J, Hildebrand M, et al. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics 1998;8:181-185.
48. Lemos MC, Cabrita FJ, Silva HA, et al. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis 1999;20:1225-1229.
49. Abraham BK, Adithan C, Shashindran CH, et al. Genetic polymorphism of CYP2D6 in a Keralite (South India) population. Br J Clin Pharmac 2000;49:285-286.
50. Abraham BK, Adithan C, Kiran UP, et al. Genetic polymorphism of CYP2D6 in Karnataka and Andhra Pradesh population in India. Acta Pharmacol Sin 2000;21:494-498.
51. Abraham BK, Adithan C, Mohanasundaram J, et al. Genetic polymorphism of CYP2D6 in Tamil population. Eur J Clin Pharmacol 2001;56:849-850.
52. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6:733-743.
53. Nair UJ, Nair J, Mathew B, et al. Glutathione S-transferase M1 and T1 null genotypes as risk factors for oral leukoplakia in ethnic Indian betal quid/tobacco chewers. Carcinogenesis 1999;20:743-748.
54. Kato S, Bowman ED, Harrington AM, et al. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J Natl Cancer Inst 1995;87:902-907.
55. Arruda VR, Lima CS, Grignoli CR, et al. Increased risk for acute myeloid leukaemia in individuals with glutathione S-transferase mu 1 (GSTM1) and theta 1 (GSTT1) gene defects. Eur J Haematol 2001;66:383-388.
56. d'Errico A, Taioli E, Chen X, et al. Genetic metabolic polymorphisms and the risk of cancer: A review of the literature. Biomarkers 1996;1:149-173.
57. Chen CL, Liu Q, Pui CH, et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 1997;89:1701-1707.
58. Lin HJ, Han CY, Bernstein DA, et al. Ethnic distribution of the glutathione Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis 1994;15:1077-1081.
59. Nelson HH, Wiencke JK, Christiani DC, et al. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis 1995;16:1243-1245.
60. Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P4501 A1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 1992;83:866-870.
61. Nakachi K, Imai K, Hayashi S, et al. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 1993;53:2994-2999.
62. Butkiewicz D, Grzybowska E, Hemminki K, et al. Modulation of DNA adduct levels in human mononuclear white blood cells and granulocytes by CYP1A1 CYP2D6 and GSTM1 genetic polymorphisms. Mutat Res 1998;415:97-108.